Response to "Survival advantage for Etoposide/Cisplatin over Paclitaxel/Carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: A subgroup analysis for ECOG 2 patients would be of great interest".
Annals of Oncology（2017）
关键词
Chemoradiotherapy,concomitant,inoperable,locally-advanced NSCLC,performance status
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要